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Lynch syndrome (LS), an autosomal dominant inherited cancer susceptibility syndrome, also known as hereditary
non-polyposis colon cancer (HNPCC), is caused by a germline mutation in one of several DNA mismatch repair
(MMR) genes. LS is the most common presentation of hereditary colorectal cancer (CRC), accounting for about
2–5% of all CRC cases. More recently, it is found that a similar number of endometrial cancers is also due to one of
the MMR gene mutations. There has been significant progress in LS-related CRC in terms of molecular
pathogenesis, risks, genetic basis, and cancer prevention. In contrast, the advance about LS-related endometrial
cancer (EC) is very much limited. In this commentary, we summarize the main clinicopathologic features of
LS-related EC and propose universal screening for LS in individuals with endometrial cancer.Lynch syndrome (LS), an autosomal dominant inherited
cancer susceptibility syndrome, also known as hereditary
non-polyposis colon cancer (HNPCC), is caused by a
germline mutation in one of several DNA mismatch re-
pair (MMR) genes: MLH1, MSH2, MSH6 or PMS2. LS
is the most common presentation of hereditary colorec-
tal cancer (CRC), accounting for about 2–5% of all CRC
cases [1,2]. There has been significant progress in LS-
related CRC in terms of molecular pathogenesis, risks,
genetic basis, and cancer prevention. Moreover, univer-
sal screening for LS in all individuals affected by CRC
has been adopted by national working groups, with algo-
rithms for cost-effective screening developed [3].
Recently, focus has shifted to LS-related endometrial
cancer (EC) as women with LS have a 40-60% chance of
presenting with EC as the first clinical manifestation [4].
From a clinical perspective, confirmation that an EC is
LS-related has the potential to influence early detection,
screening, and prevention of other LS-associated can-
cers, more so than a diagnosis of LS related CRC. Many
countries, including United States, have started screening* Correspondence: SChambers@uacc.arizona.edu; zhengw@email.arizona.edu
†Equal contributors
2Department of Obstetrics and Gynecology, University of Arizona, Tucson,
AZ, USA
3Department of Pathology, University of Arizona College of Medicine,
Tucson, AZ, USA
Full list of author information is available at the end of the article
© 2013 Wang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpatients with EC to identify those with LS, thereby leading
to earlier screening for CRC. Earlier screening would aim
to either prevent CRC or detect it in earlier stages [5]. In
that 50% of LS patients present with endometrial cancer
first, diagnosis of LS at the time of diagnosis of the endo-
metrial cancer, may prove to be a cost-effective approach,
although currently untested. It may be more cost effective
mainly because the mortality of CRC is much higher than
that of EC. At this time, although several groups nationally
are now focusing on LS-related ECs, research on LS-
related EC is still evolving. The majority of physicians and
health care providers are not aware of the clinicopatho-
logic features of LS-related EC. Further, many are unclear
as to how to make the diagnosis of LS-related EC from
clinicopathologic perspective and how to best confirm the
diagnosis of LS on a genetic level. In this commentary, we
summarize the main clinicopathologic features of LS-
related EC and propose universal screening for LS in indi-
viduals with endometrial cancer.The genetic changes in LS-related EC and its
clinical impact
Among LS-related EC, the mutation rate of MMR genes
shows a frequency in the MSH2 gene of 50-66%, in
MLH1 of 24-40%, and in MSH6 of 10-13%, respectively
[6]. Compared with EC, the gene mutation rate in LS-
related CRC is either similar or slightly less frequent, ie.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mutation is the second most frequent in LS-related EC
as well as in LS-related CRCs. Although the overall mu-
tation rate of MSH6 is relatively low (10-13%), it is
closely associated with LS-related ECs [6,7], while the
rate of PMS2 mutation is less than 5% [8], which has the
lowest frequency.
The main function of MMR is to maintain genomic
stability by correcting mismatches generated during
DNA replication. MMR malfunction results in a mutated
phenotype and microsatellite instability (MSI), which
promotes cancer formation [9]. In endometrial cancers,
MSI is very common and while a hallmark of LS, MSI is
not equivalent to LS. MSI is also present in 15–25% of
corresponding sporadic cancers [10]. In this context,
there are two conditions which may result in MSI. One
is where hypermethylation of the MLH1 gene promoter
results in gene silencing, leading to MSI. Hypermethyla-
tion is an epigenetic event thus is common in patients
with sporadic EC. The second condition is where a germ
line mutation of one or more of the above mentioned
MMR genes can induce MSI resulting in development of
LS [11].
Based on the above characteristics, in endometrial
cancers, MSI detection is not specific thus not very help-
ful in the diagnosis of LS. Therefore, a practical ap-
proach is needed to find LS-related EC patients for both
early detection and prevention of other LS-associated
cancers.
The clinicopathological features of LS-related EC
It is being recognized that, in LS, the risk of EC is equal
to, or higher than the risk of CRC. Lifetime risk of LS-
related EC is associated with age and a mutation of a
specific MMR gene. Patients with MSH6 mutations are
at higher risk (64–71%) for developing EC than those
with MSH2 or MLH1 mutations (40–50%) [12,13]. They
are also at significantly higher risk of developing EC
than CRC. It has long been thought that LS-related EC
occurs at younger ages than in sporadic cases. In one
study, the mean age at diagnosis for LS-related EC was
49 years compared to 60 years for EC in the general
population [14]. In an unselected cohort of endometrial
cancers with age younger than 50 years, the incidence of
LS was 9% [15]. However, others [16] have found the
mean age in a prospective unselected cohort to be 54
years. If an age cut-off of 50 years old had been selected
instead for LS screening, 60% of patients would have
been missed [17]. In fact, others have described that 25%
of LS patients do not fit standard screening criteria, such
as the Amsterdam, Bethesda, and SGO criteria, where
age is a prominent factor (cut-off age 50) [18].
It is interesting to note that LS-related EC sometimes
is accompanied (synchronous, or metachronous) byLS-related ovarian cancer. In fact in LS, the lifetime risk
for endometrial cancer is 40-60%, and for ovarian cancer,
9-12% [19]. The latter is usually clear cell carcinoma and
can present independently and less frequency [4,20].
Compared to LS-related EC cases, LS-related ovarian
cancer tends to have a higher MSH2 mutation rate and
occurs in a younger age, average of 45 years old [21].
For patients with LS-related EC, the risk of developing a
second cancer is estimated at 25% in 10 years and 50%
at 15 years following initial EC diagnosis [22,23]. In LS,
50% of the time, endometrial cancers present first before
the CRC diagnosis, if the diagnoses are not synchronous.
Therefore, EC can serve as a ‘sentinel’ cancer for patients
themselves and potentially for their family members.
Optimally, this provides adequate time to screen for a
second cancer leading to either prevention or earlier
diagnosis and treatment.
Clinically, studies have revealed that patients with LS-
related EC have unique features. Both Type 1 and Type
2 ECs are part of LS [24-26]. In the general population,
non-endometrioid EC is typically diagnosed in older
women with a mean age of 65 to 68 years [27,28]. In LS,
however, the mean age of diagnosis of these non-
endometrioid tumors is 46.4 years, similar to the mean
age of LS-related EC overall (46.8 years) [25]. Patients
with LS-related EC often have no evidence of estrogen
overstimulation such as obesity, diabetes, exogenous es-
trogen usage, and polycystic ovarian syndrome. Patients
may present irregular bleeding, but it is less likely to be
found to have endometrial hyperplasia prior to EC diag-
nosis. LS-related EC is suspected when a patient is diag-
nosed with EC, but presents without risk factors known
to be associated with EC. In addition, low body mass
index, relatively young age, and positive family history
LS or LS-related cancers should raise suspicion of LS-
related EC [29,30].
Pathologically, there is considerable literature on the
presence or absence of distinctive microscopic features
in LS-related EC. Historically, many studies correlated
the morphologic features of MSI and MLH1 methylation
status. In addition, there are many studies correlation
LS-related EC to MMR gene mutation status. We sum-
marize the overall pathologic features for LS-related EC
as follows:
(1) LS-related ECs tend to be more histologically
diverse and can include endometrioid and non-
endometrioid histotypes. Clear cell carcinoma,
endometrial serous carcinoma, undifferentiated
carcinoma, and carcinosarcoma all have been
identified as non-endometrioid histology in LS-
related ECs [24-26]. In contrast, sporadic ECs that
have MSI due to MLH1 methylation are
predominantly endometrioid, especially FIGO
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histotype reaching 96% [25].
(2) Microscopic features that have been associated with
the presence of high level of MSI include poor
differentiation, mucinous features, signet ring cell
differentiation, mixed tumor histology, tumor cells
growing in a medullary-type pattern, increased
tumor-infiltrating lymphocytes, and a Crohn-like
inflammatory infiltrate at the tumor invading front
or periphery [17].
(3) LS-related EC cases also have a tendency to involve
low uterine segment (LUS). Westin et al. showed
that a relatively high percentage (34%) of the LUS
cancers had a high level of MSI. Among them, 29%
of the LUS ECs were confirmed to be from women
with LS [31]. This percentage of LS-related EC with
LUS location is extremely high when compared
with the incidence of LUS involvement in non LS-
related EC [25,32,33]. In addition, LS-related EC
with LUS involvement is also more associated with
hMSH2 mutations [6].
Although the published data for LS-related EC is lim-
ited, it is our opinion that these pathologic features are
not sufficiently sensitive and specific to be used in the
clinical setting as accurate predictors of the presence of
LS. However, they do raise suspicion of LS. Therefore,
appropriate tissue testing (described below) followed as
appropriate with genetics counseling with germline
DNA mutational analysis for suspected MMR genes are
needed to confirm if LS is present.
Tissue testing for Lynch syndrome from women
with endometrial cancer
Tissue testing (immunohistochemistry for MMR pro-
teins, MSI analysis, and MLH1 methylation analysis) has
been used as a practical first step in the evaluation of in-
dividuals thought to be at risk for having LS. Practically,
each of these tests can be performed using formalin-
fixed, paraffin-embedded tissues and commercially avai-
lable antibodies. In many institutions, MSI analysis is
performed in parallel with immunohistochemistry for
MLH1, MSH2, MSH6, and PMS2. It requires both tu-
mor and normal non-tumor tissues. For endometrial
cancer, adjacent benign endometrium and stromal cells
in addition to normal cervix or ovarian tissues could be
used as normal controls. For those tumors with MSI and
loss of MLH1 by immunohistochemistry, a PCR-based
assay to detect for hypermethylation of the MLH1 pro-
moter is performed. If methylation is present, it is much
more likely that the patient has a sporadic endometrial
carcinoma rather than a LS-related EC. For CRC, BRAF
mutation is also an explanation for loss of MLH1 pro-
tein expression. However, studies [16] of EC specimensshow that BRAF mutation is very rare, thus BRAF muta-
tion testing is not recommended in endometrial cancers
when MLH1 loss is seen. The MLH1 and PMS2 proteins
and the MSH2 and MSH6 proteins act as functional
pairs, forming heterodimers [34]. Mutation of MLH1 or
methylation of MLH1 typically results in loss of im-
munhistochemical expression of both MLH1 and PMS2.
Similarly, mutation of MSH2 usually results in immuno-
histochemical loss of both MSH2 and MSH6. However,
mutation of MSH6 alone usually is associated with loss
of MSH6 protein but retention of MSH2 by immunohis-
tochemistry. Similarly, mutation of PMS2 is typically as-
sociated with loss of PMS2 protein but retained MLH1
immunohistochemical expression.Which patients with endometrial cancer should be
evaluated for Lynch syndrome?
Nationally, universal screening for LS in endometrial
cancer patients is being advocated, and implemented by
several centers. Algorithms for such screening have been
developed [16,35]. In many centers, universal screening
for CRC has already been implemented. The incidence
in unselected populations of LS in EC patients is
2.3% [17], which approaches the 3% rate of LS in
CRC patients. Usage of standard criteria such as the
Amsterdam, Bethesda, or SGO criteria has led to un-
derestimation of the true rate of EC in LS patients.
Endometrial cancer is the most common gynecologic
malignancy and is the sentinel event in LS 50% of the
time.
Thus, we advocate for universal screening in endome-
trial cancer patients, with an age cut-off of 60, as the
mean age of LS-related EC is over the age of 50.
However, for EC patients who are older than 60, the
screening test will be offered selectively based on clini-
copathologic findings. This is mainly because that elderly
patient may have a high tendency of MMR gene dys-
function. Patients should be screened first by immuno-
histochemical detection of the MMR proteins, not with
MSI. If MLH1 loss is seen, hypermethylation of MLH1
should be performed. BRAF mutation does not have a
major role in endometrial cancers, thus is not included
in this screening algorithm. If there is a loss in MSH2,
MSH 6, or PMS 2 alone, germline testing for mutations
in those genes is recommended. If there is a loss in
MLH1 not explained by hypermethylation, then germ-
line MLH1 gene testing is recommended. If losses are
seen in both MLH1 and PMS2, then the MLH1 loss is
considered primary, and should be worked up as above.
Similarly, if losses are seen in both MSH2 and MSH6,
MSH2 is considered the primary event and germline
testing for MSH2 is recommended (Figure 1, as an algo-
rithm below).
Figure 1 Algorithm of screening patients with endometrial cancer for Lynch syndrome. This algorithm does not cover the rare finding of
Cowden’s Syndrome. Referral to the genetics counselor can always be made in any situation where the clinicopathologic suspicion is strong for
Lynch syndrome.
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be selected for screening. Both gynecologists and pathol-
ogists are in a position to identify EC patients who may
be presenting with a sentinel manifestation of LS. Close
interaction between gynecologists and gynecologic pa-
thologists will further facilitate identifying LS in clinical
practice. Others [15,36] have suggested selection criteria
for LS screening of endometrial cancers. We advocate
that the following clinical characteristics may provide
important signs for clinicians that LS-related EC should
be suspected with a diagnosis of EC:
(1) Patients, particularly with pathologic diagnosis as
endometrioid carcinoma, show no evidence of
estrogen overstimulation such as low body mass
index (no obesity), no history of polycystic ovarian
syndrome, nor unopposed estrogen usage;
(2) Patients with a synchronous endometrial and
ovarian cancer, particularly clear cell carcinoma of
the ovary;
(3) Patients with a family history of apparent LS;
(4) Patients with a personal history colon cancer;
Further, pathologists, particularly gynecologic patholo-
gists, should be suspicious of LS for EC cases with the
following pathologic characteristics:(1) Endometrioid carcinoma without hyperplastic
endometrium in the background;
(2) Heterogeneous cancer pathology such as one area
with well differentiated carcinoma, but another area
with different pathologic patterns such poor
differentiation, mucinous features including signet
ring cells, and medullary growth pattern;
(3) Tumor-infiltrating lymphocytes or a Crohn-like
inflammatory infiltrate invading either front or
periphery;
(4) Predominantly low uterine segment location after
excluding cervical primary;
(5) Well differentiated (FIGO grade 1) endometrioid
carcinoma but with more than 50% myometrial
invasion;
(6) History of well differentiated endometrioid
carcinoma with recurrence within 2 years after
ruling out endometrial serous or clear cell
carcinoma.
It is imperative that pathologists communicate with
corresponding gynecologists prior to ordering the MMR
protein immunohistochemical stains, if the institution is
not prepared to implement universal screening for EC
patients. Although the above clinicopathologic findings
are neither specific nor sensitive, we think this may be a
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for LS prior to developing other LS related cancers.
Based on the current understanding and clinical ex-
perience gained, we are advocating universal screening
for patients who are 60 years or younger, and selective
screening for those patients older than 60 years based
on clinicopathologic findings (see screening algorithm
above).
Future directions
Our understanding of clinicopathologic features, patho-
genesis, and the individual role of MMR gene mutation
of LS-related ECs is continuing to evolve. Many studies
including large scale clinical studies are needed to fur-
ther characterize the above parameters in order to de-
velop efficient surveillance systems and genetic tests in
order to provide ideal diagnostic, therapeutic, and preven-
tion modalities for the majority of LS-related cancers.
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